feed,title,long_url,short_url
Benzinga,Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-Bâ„¢,https://benzinga.com/general/biotech/23/12/36090339/longeveron-nasdaq-lgvn-announces-positive-top-line-results-for-its-phase-2a-clinical-trial-for-th,https://da.gd/JYCZ4
